The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). (Q50912623)
Jump to navigation
Jump to search
scientific article published on 31 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). |
scientific article published on 31 January 2017 |
Statements
The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL) (English)
Mohiuddin Gazi
Sausan A Moharram